Health · 7 views
Commonly mutated gene could be a therapeutic target in sarcoma
Researchers at The University of Texas MD Anderson Cancer Center have discovered that sarcomas lacking the ATRX gene tend to be more aggressive and may be particularly vulnerable to a class of targeted therapies known as TEAD inhibitors.
AI Summary
Researchers at the University of Texas MD Anderson Cancer Center found that sarcomas without the ATRX gene are more aggressive. The loss of ATRX correlates with a poorer prognosis. These tumors may be especially sensitive to TEAD inhibitors, a class of targeted therapies. The study suggests ATRX loss could serve as both a prognostic marker and a therapeutic target.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- What is 'intergenerational trauma'? A social worker explains how one generation's experiences can affect descendantsContinue reading
- Respiratory Virus Activity - United States, July 2025-June 2026Continue reading
- Doctor's Worst Nightmare; Measles Status Backlash; More Testing, Better Care?Continue reading
- The 'Magic Six': How to strengthen your marriage in midlifeContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow